Two First-Line HIV Regimens Meet at the Crossroads of Suppression and Weight Gain
Initial antiretroviral therapy has always been judged by a simple standard: stop viral replication quickly and keep treatment durable enough for the long haul. In this randomized clinical trial, the comparison moved beyond virologic control and into a problem that has become increasingly difficult to ignore in routine HIV care — treatment-associated weight gain.
Adults with HIV who had not previously received antiretroviral therapy were assigned to one of two first-line regimens: doravirine, lamivudine, and tenofovir disoproxil fumarate, or dolutegravir, emtricitabine, and tenofovir alafenamide. The study centered on two endpoints that matter at the bedside for very different reasons. Viral suppression determines whether the regimen does its core job. Weight change determines whether a patient’s metabolic trajectory shifts in a direction that may complicate cardiovascular risk, patient acceptance, and long-term adherence.
The pairing is clinically revealing. Dolutegravir-based regimens and tenofovir alafenamide have both been linked in prior clinical discussion to upward shifts in body weight in some patients, while doravirine and tenofovir disoproxil fumarate have often been viewed as more weight-neutral comparators. A head-to-head trial in treatment-naive adults therefore asks more than which regimen controls HIV. It asks whether the metabolic footprint of modern first-line therapy differs enough to influence regimen selection before the first prescription is written.
One sentence captures the tension in this study: virologic success alone is no longer the only acceptable outcome.
Why Weight Gain Has Become Part of First-Line HIV Decision-Making
The biology behind antiretroviral-associated weight change remains incompletely defined, but the clinical signal is hard to dismiss. Several mechanisms may contribute at once: recovery from untreated HIV can reverse catabolic illness, removal of older drug toxicities can unmask regain, and specific agents may influence adipocyte biology, appetite, or energy balance in ways that are still being clarified. In practice, the consequence is straightforward. A regimen that suppresses virus effectively but drives substantial excess weight gain may alter future cardiometabolic risk, especially in patients already vulnerable to obesity, insulin resistance, or hypertension.
That concern is particularly relevant when treatment starts in adulthood and may continue for decades. A first regimen is not a short experiment. It becomes the platform on which future treatment decisions, adherence patterns, and metabolic monitoring are built. For that reason, comparing dolutegravir-based therapy with a doravirine-based alternative is not an academic exercise. It reflects the real-world need to choose a regimen that balances potency with tolerability in the broadest sense.
The study design also carries practical importance because both regimens are built from widely used agents. Lamivudine and emtricitabine are established nucleoside analogues, while tenofovir disoproxil fumarate and tenofovir alafenamide differ in pharmacologic exposure and adverse-effect profile. Those differences matter when long-term therapy is the rule rather than the exception. The trial therefore sits at the intersection of virology and metabolic medicine, where first-line HIV prescribing increasingly lives.
What the Randomized Comparison Was Positioned to Answer
The key question was not whether either regimen can suppress HIV. Both combinations are credible first-line options, and the trial was designed to compare their effects on weight gain and viral suppression in adults without prior antiretroviral exposure. That dual focus reflects a shift in HIV care. Clinicians now expect near-universal viral control from modern regimens, so differences that once seemed secondary can become decisive if they affect body composition, patient satisfaction, or downstream metabolic health.
A trial like this also has an immediate bedside echo. When weight rises after ART initiation, the reflex is often to blame lifestyle alone. Yet if one regimen consistently produces more gain than another, the medication itself becomes part of the differential diagnosis. That distinction can shape counseling, follow-up frequency, and future switching decisions. It may also change the tone of the first visit, when patients are often trying to understand not just whether treatment will work, but what treatment will do to their bodies over time.
Why These Regimens Invite Different Metabolic Expectations
The regimen built on dolutegravir and tenofovir alafenamide has attracted attention because both components have been associated in clinical practice with greater-than-expected increases in weight in some cohorts. Tenofovir alafenamide delivers lower plasma tenofovir exposure than tenofovir disoproxil fumarate, and that pharmacologic shift may contribute to differences in weight and lipid behavior, although causality is not fully settled. Dolutegravir, as an integrase strand transfer inhibitor, has also been part of the broader conversation about modern ART and weight gain.
On the other side of the comparison, doravirine offers a distinct nonnucleoside reverse transcriptase inhibitor backbone, paired here with lamivudine and tenofovir disoproxil fumarate. The combination has often been considered more metabolically conservative. Whether that expectation holds up in randomized data is exactly the kind of question that changes prescribing habits, especially when viral suppression is expected to be strong in both arms.
These pharmacologic contrasts are especially important because weight gain in HIV care is not merely cosmetic. Excess gain can alter blood pressure, glucose regulation, and lipid profiles over time. In a chronic infection now managed as a long-term condition, those outcomes matter as much as the first undetectable viral load.
The Clinical Meaning of a Head-to-Head Weight Endpoint
A trial focused on treatment-associated weight gain signals that HIV medicine is moving toward fuller accounting of harm and benefit. That shift is overdue. Patients live with the cumulative effects of therapy, not just with virologic endpoints at fixed intervals. Regimens with equivalent antiviral activity may differ meaningfully in the way they affect body composition, and those differences can influence adherence, self-image, and long-term cardiovascular risk management.
The design also raises a broader issue in contemporary HIV care: success is no longer defined by suppression alone. If two regimens can both keep HIV controlled, then selection increasingly depends on the burden of tradeoffs each one imposes. Weight gain has become one of those tradeoffs, and a randomized comparison like this gives clinicians a framework for discussing it with patients before treatment begins.
For now, the trial establishes the right question and the right comparison. It places doravirine plus lamivudine and tenofovir disoproxil fumarate against dolutegravir plus emtricitabine and tenofovir alafenamide in untreated adults with HIV, with viral suppression and weight gain as the central outcomes. The abstract does not provide the numerical results, so no claim can be made here about which regimen produced greater suppression or more weight change. What is already clear is the clinical framework: in first-line HIV therapy, metabolic consequences now sit beside virologic efficacy as a defining measure of treatment choice.